X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (50) 50
humans (44) 44
female (34) 34
middle aged (34) 34
oncology (27) 27
male (26) 26
adult (23) 23
aged (22) 22
article (19) 19
cancer (17) 17
hematology (15) 15
prognosis (15) 15
aged, 80 and over (12) 12
leukemia, myeloid, acute - drug therapy (11) 11
adolescent (10) 10
breast neoplasms - drug therapy (10) 10
treatment outcome (10) 10
animals (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
chemotherapy (9) 9
leukemia, myeloid, acute - genetics (9) 9
young adult (9) 9
abridged index medicus (8) 8
acute myeloid-leukemia (8) 8
clinical trials (8) 8
disease-free survival (8) 8
neurosciences (8) 8
research (8) 8
therapy (8) 8
aml (7) 7
analysis (7) 7
antineoplastic agents, hormonal - therapeutic use (7) 7
hemic and lymphatic diseases (7) 7
impact (7) 7
mutation (7) 7
postmenopausal women (7) 7
schizophrenia (7) 7
acute myelogenous leukemia (6) 6
breast cancer (6) 6
cytogenetics (6) 6
group-b (6) 6
leukemia, myeloid, acute - mortality (6) 6
schizophrenia - pathology (6) 6
tamoxifen - therapeutic use (6) 6
acute myeloid leukemia (5) 5
aromatase inhibitor (5) 5
daunorubicin - administration & dosage (5) 5
flow cytometry (5) 5
health aspects (5) 5
kaplan-meier estimate (5) 5
medicine & public health (5) 5
myelodysplastic syndromes - drug therapy (5) 5
oncology, experimental (5) 5
prefrontal cortex (5) 5
survival (5) 5
survival rate (5) 5
tamoxifen (5) 5
adult patients (4) 4
antibiotics, antineoplastic - administration & dosage (4) 4
apoptosis (4) 4
aromatase inhibitors (4) 4
care and treatment (4) 4
chemistry (4) 4
clinical trials and observations (4) 4
double-blind method (4) 4
follow-up studies (4) 4
gene-expression (4) 4
hematology, oncology and palliative medicine (4) 4
letrozole (4) 4
leukemia (4) 4
macaca fascicularis (4) 4
medical prognosis (4) 4
medicine (4) 4
metallurgy (4) 4
mice (4) 4
multivariate analysis (4) 4
myeloid leukemia (4) 4
neoplasms (4) 4
nitriles - administration & dosage (4) 4
nitriles - therapeutic use (4) 4
original reports (4) 4
pathology (4) 4
performing operations (4) 4
poor-prognosis (4) 4
postmenopause (4) 4
psychiatry (4) 4
remission induction (4) 4
research article (4) 4
retrospective studies (4) 4
signal transduction (4) 4
survival analysis (4) 4
tamoxifen - administration & dosage (4) 4
transporting (4) 4
trial (4) 4
triazoles - administration & dosage (4) 4
triazoles - therapeutic use (4) 4
analysis of variance (3) 3
anastrozole (3) 3
antimetabolites, antineoplastic - administration & dosage (3) 3
antineoplastic agents - therapeutic use (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 12, pp. 1079 - 1089
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 13, pp. 1249 - 1259
Patients with AML who were between 17 and 60 years of age were randomly assigned to receive induction therapy with the standard dose of daunorubicin or twice... 
CYTOSINE-ARABINOSIDE | MEDICINE, GENERAL & INTERNAL | ONCOLOGY-GROUP | INDUCTION CHEMOTHERAPY | ACUTE NONLYMPHOCYTIC LEUKEMIA | ACUTE MYELOGENOUS LEUKEMIA | ACUTE MYELOCYTIC-LEUKEMIA | GROUP-B | DAUNORUBICIN | REMISSION INDUCTION | UNTREATED ADULT PATIENTS | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Leukemia, Myelomonocytic, Acute - drug therapy | Stem Cell Transplantation | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myelomonocytic, Acute - therapy | Adult | Female | Remission Induction - methods | Daunorubicin - administration & dosage | Leukemia, Myelomonocytic, Acute - genetics | Histone-Lysine N-Methyltransferase | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Combined Modality Therapy | Cytarabine - administration & dosage | Daunorubicin - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Myeloid-Lymphoid Leukemia Protein - genetics | Adolescent | Infusions, Intravenous | Mutation | Leukemia, Myelomonocytic, Acute - mortality | Anthracyclines | Usage | Daunorubicin | Young adults | Health aspects | Bone marrow | Chemotherapy | Consolidation | Kinases | Index Medicus | Abridged Index Medicus
Journal Article
Nature Neuroscience, ISSN 1097-6256, 02/2006, Volume 9, Issue 2, pp. 251 - 259
Journal Article
Journal Article
American Journal of Psychiatry, ISSN 0002-953X, 06/2005, Volume 162, Issue 6, pp. 1200 - 1202
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2012, Volume 7, Issue 8, pp. e43826 - e43826
Despite rapid advances in chemotherapy and surgical resection strategies, pancreatic cancer remains the fourth leading cause of cancer related deaths in the... 
IN-VITRO | ACTIVATION | INHIBITION | MULTIDISCIPLINARY SCIENCES | DOWN-REGULATION | CYCLE CHECKPOINTS | PROLIFERATION | INDUCTION | NF-KAPPA-B | BCL-2 FAMILY | EXPRESSION | Cell Survival - drug effects | Triterpenes - pharmacology | Apoptosis - drug effects | Humans | Pancreatic Neoplasms - pathology | Deoxycytidine - pharmacology | NF-kappa B - metabolism | Protein Transport - drug effects | DNA - metabolism | Drug Synergism | Proto-Oncogene Proteins c-bcl-2 - metabolism | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | G1 Phase Cell Cycle Checkpoints - drug effects | Anticarcinogenic Agents - pharmacology | Deoxycytidine - analogs & derivatives | Complications and side effects | Gemcitabine | Pancreatic cancer | Cancer cells | Physiological aspects | Genetic aspects | Dosage and administration | Research | Drug therapy | Cell proliferation | Bcl-2 protein | Transcription | Kinases | Caspase-3 | Cancer therapies | Cyclin-dependent kinase 4 | Proteins | Cell growth | Surgery | Cell cycle | Inhibition | Deoxyribonucleic acid--DNA | Binding | Translocation | NF-κB protein | Caspase | Pharmacology | Chemical compounds | Cyclins | Cyclin-dependent kinase 2 | Cyclin-dependent kinase inhibitor p21 | Chemotherapy | Cell death | Medical prognosis | Cyclin-dependent kinase inhibitor p27 | Prostate | Cancer | Apoptosis | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
Journal Article
Cancer Cell, ISSN 1535-6108, 2010, Volume 18, Issue 6, pp. 553 - 567
Journal Article
Journal Article